Hanall Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Hanall Biopharma wird ein jährliches Gewinn- und Umsatzwachstum von 61.1% bzw. 13.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 98.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.1% betragen.

Wichtige Informationen

61.1%

Wachstumsrate der Gewinne

98.3%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	31.4%
Wachstumsrate der Einnahmen	13.4%
Zukünftige Eigenkapitalrendite	12.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	25 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Oct 14

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Jun 26

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

May 22

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Mar 13

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Feb 12

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Jan 25

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 04

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Dec 14

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Nov 21

Gewinn- und Umsatzwachstumsprognosen

KOSE:A009420 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (KRW Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	190,417	58,575	44,133	46,000	6
12/31/2025	165,733	22,880	24,400	27,233	6
12/31/2024	140,750	-3,000	7,300	9,300	2
9/30/2024	134,245	-6,288	-10,130	8,834	N/A
6/30/2024	130,374	-6,191	7,368	23,537	N/A
3/31/2024	140,199	4,439	11,622	22,456	N/A
12/31/2023	134,910	3,509	20,445	29,643	N/A
9/30/2023	133,308	6,049	20,476	29,993	N/A
6/30/2023	129,981	6,464	2,734	10,524	N/A
3/31/2023	114,812	-919	10,130	18,084	N/A
12/31/2022	109,995	251	17,587	25,264	N/A
9/30/2022	104,764	-376	10,636	20,123	N/A
6/30/2022	100,596	949	10,515	20,067	N/A
3/31/2022	97,783	4,288	1,719	12,083	N/A
12/31/2021	101,594	8,896	-8,162	840	N/A
9/30/2021	98,500	16,123	72	6,659	N/A
6/30/2021	95,140	17,778	-4,183	1,719	N/A
3/31/2021	94,304	20,413	-5,913	1,778	N/A
12/31/2020	88,602	19,765	-6,460	929	N/A
9/30/2020	92,953	19,714	-20,156	-7,468	N/A
6/30/2020	98,834	21,457	1,452	14,085	N/A
3/31/2020	106,049	19,753	13,739	22,030	N/A
12/31/2019	108,452	19,174	12,215	20,491	N/A
9/30/2019	105,550	10,279	22,576	24,374	N/A
6/30/2019	101,531	7,373	10,174	11,694	N/A
3/31/2019	94,252	5,882	3,130	5,117	N/A
12/31/2018	91,839	3,300	-4,913	-2,994	N/A
9/30/2018	88,551	9,000	26,226	28,359	N/A
6/30/2018	89,131	9,149	N/A	28,894	N/A
3/31/2018	87,204	6,945	N/A	33,291	N/A
12/31/2017	84,231	5,813	N/A	42,139	N/A
9/30/2017	85,417	3,586	N/A	7,912	N/A
6/30/2017	81,809	562	N/A	-325	N/A
3/31/2017	81,807	1,355	N/A	2,825	N/A
12/31/2016	82,882	2,026	N/A	3,950	N/A
9/30/2016	82,223	-3,478	N/A	6,046	N/A
6/30/2016	79,584	-5,817	N/A	6,546	N/A
3/31/2016	79,447	-7,142	N/A	2,205	N/A
12/31/2015	80,023	-7,077	N/A	-454	N/A
9/30/2015	79,818	-16,050	N/A	1,128	N/A
6/30/2015	81,892	-13,143	N/A	280	N/A
3/31/2015	81,657	-12,865	N/A	-1,115	N/A
12/31/2014	80,880	-12,658	N/A	-3,518	N/A
9/30/2014	78,763	-11,694	N/A	-6,993	N/A
6/30/2014	77,511	-17,134	N/A	-5,677	N/A
3/31/2014	76,276	-18,966	N/A	-8,556	N/A
12/31/2013	74,228	-21,499	N/A	-7,780	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: A009420 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.7%).

Ertrag vs. Markt: A009420 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: A009420 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: A009420Die Einnahmen des Unternehmens (13.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt KR (9.1% pro Jahr).

Hohe Wachstumseinnahmen: A009420Die Einnahmen des Unternehmens (13.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: A009420Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.1%).

Hanall Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates increase by 23%, revenue downgraded

Consensus EPS estimates fall by 45%, revenue upgraded

Consensus EPS estimates fall by 12%

Price target increased by 11% to ₩44,667

Price target increased by 8.5% to ₩42,333

Consensus EPS estimates increase by 16%

Recent updates

Hanall Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of A First-In-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

Now 23% undervalued

Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Consensus EPS estimates increase by 23%, revenue downgraded

Now 22% undervalued after recent price drop

Hanall Biopharma Co., Ltd. Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

Hanall Biopharma Co., Ltd. Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Consensus EPS estimates fall by 45%, revenue upgraded

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

Consensus EPS estimates fall by 12%

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Hanall Biopharma Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings released: EPS: ₩69.00 (vs ₩5.00 in FY 2022)

Price target increased by 11% to ₩44,667

Price target increased by 8.5% to ₩42,333

Consensus EPS estimates increase by 16%

New major risk - Share price stability

Price target increased by 14% to ₩35,800

Now 20% undervalued

Full year 2022 earnings released: EPS: ₩5.00 (vs ₩174 in FY 2021)

Less than half of directors are independent

Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner

Price target decreased to ₩29,000

Less than half of directors are independent

Price target decreased to ₩45,500

First quarter 2021 earnings released: EPS ₩88.00 (vs ₩76.00 in 1Q 2020)

Hanall Biopharma Co.,Ltd, Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS ₩386 (vs ₩375 in FY 2019)

New 90-day low: ₩23,400

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Investor sentiment deteriorated over the past week

New 90-day low: ₩32,050

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: ₩39,000

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Market bids up stock over the past week

New 90-day low: ₩27,600

Price target raised to ₩41,500

New 90-day high - ₩34,600

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken